• linkedin
  • Increase Font
  • Sharebar

    10 More Newly Approved Drugs

    The FDA is having a productive 2017.


    Older female

    RYDAPT­ (midostaurin), Novartis

    Indications: Newly diagnosed acute myeloid leukemia (AML) that is FLT3 mutation-positive as detected by an FDA-approved test, in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation. Not indicated as a single-agent induction therapy for the treatment of patients with AML. Aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematological neoplasm (SM-AHN), or mast cell leukemia. Strong CYP3A4 Inhibitors: Strong CYP3A4 inhibitors may increase (MCL).

    Dosage: AML: 50 mg orally twice daily with food. ASM, SM-AHN, and MCL: 100 mg orally twice daily with food.

    Contraindications: Hypersensitivity to midostaurin or any of the excipients.

    Read the prescribing information here

    Previous ButtonNext Button



    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available